BRPI0509221A -
epothilone and carboplatin combination therapies
- Google Patents
epothilone and carboplatin combination therapies
Info
Publication number
BRPI0509221A
BRPI0509221ABRPI0509221-3ABRPI0509221ABRPI0509221ABR PI0509221 ABRPI0509221 ABR PI0509221ABR PI0509221 ABRPI0509221 ABR PI0509221ABR PI0509221 ABRPI0509221 ABR PI0509221A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/088,534external-prioritypatent/US20050215604A1/en
Application filed by Kosan Biosciences IncfiledCriticalKosan Biosciences Inc
Publication of BRPI0509221ApublicationCriticalpatent/BRPI0509221A/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
"TERAPIAS DE COMBINAçãO COM EPOTILONAS E CARBOPLATINA. A presente invenção refere-se a uma terapia de combinação de uma epotilona e uma carboplatina que é eficaz para tratar tumores.EPOTILONE AND CARBOPLATIN COMBINATION THERAPIES. The present invention relates to a combination therapy of an epothilone and a carboplatin that is effective for treating tumors.
BRPI0509221-3A2004-03-262005-03-24
epothilone and carboplatin combination therapies
BRPI0509221A
(en)
combination therapy comprising a tor kinase inhibitor and n- (3- (5-fluoro-2- (4- (2-methoxyethoxy) phenylamino) pyrimidin-4-ylamino) phenyl) acrylamide for cancer treatment